193010-16-1

Upstream product

• 219572-67-5 ethyl 4-(acetylamino)-3-((2,4-dichlorobenzyl)-amino)benzoate 
• 193009-93-7 1-(2,4-dichlorobenzyl)-6-(ethoxycarbonyl)-2-methylbenzimidazole 

Downstream Products

• 193012-35-0 FK₆₁₄ 
• 280581-71-7 1-(2,4-dichlorobenzyl)-2-methyl-6-((3-methylbenzene)sulfonylcarbamoyl)benzimidazole 
• 193011-29-9 6-benzenesulfonylcarbamoyl-1-(2,4-dichlorobenzyl)-2-methylbenzimidazole hydrochloride 

Relevant academic research and scientific papers

Benzimidazole derivatives

A novel benzimidazole derivative or a salt thereof is provided, which is represented by the formula: wherein R1represents an alkyl group, etc., R2represents a substituted or unsubstituted aromatic lower alkyl group, R3represents an alkyl group, etc., and -X- is represented by the following formula (V): etc. This derivative or a salt thereof is useful as medicine.

Method of inhibiting neoplastic cells with benzimidazole derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to benzimidazole derivatives.

Benzimidazole compounds

A benzimidazole compound represented by the formula (I): wherein R3is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.

REMEDIES FOR POLYCYSTIC OVARY SYNDROME

The present invention relates to a therapeutic agent for polycystic ovary syndrome, which comprises a compound of the following formula (1) or (2), or a pharmaceutically acceptable salt thereof as an active ingredient: wherein each symbol is as defined in the specification.

BENZIMIDAZOLE DERIVATIVES

The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof: wherein R1 represents a lower alkyl group or a lower alkyloxy-lower alkyl group: R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an aryl group, and such; R3 represents a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylaryl group, an aryl-lower alkenyl group, a halothienyl group, a lower alkylamino group, or an aryl-lower alkylamino group; A represents a benzene ring, a naphthalene ring, or a pyridine ring; and X represents a halogen atom. The derivatives and their salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful as pharmaceutical preparations.

Benzimidazole derivatives

PCT No. PCT/JP96/03858 Sec. 371 Date Nov. 2, 1998 Sec. 102(e) Date Nov. 2, 1998 PCT Filed Dec. 27, 1996 PCT Pub. No. WO97/24334 PCT Pub. Date Jul. 10, 1997Novel benzimidazole derivatives represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.